A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡
Kittichai Promrat, Glen A. Lutchman, Gabriel Ikponmosa Uwaifo et al. · Hepatology · 2004
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibrosis and cirrhosis. NASH is considered one of the clinical features of the metabolic syndrome in which insulin resistance plays a central role. This prospective study evaluates the role of insulin-sensitizing agent in treatment of NASH. Eighteen nondiabetic patients with biopsy-proven NASH were treated with pioglitazone (30 mg daily) for 48 weeks. Tests of insulin sensitivity and body composition as well as liver biopsies were performed before and at the end of treatment. By 48 weeks, serum alanine aminotransferase values fell to normal in 72% of patients. Hepatic fat content and size as determined by magnetic resonance imaging decreased, and glucose and free fatty acid sensitivity to insulin were uniformly improved. Histological features of steatosis, cellular injury, parenchymal inflammation, Mallory bodies, and fibrosis were significantly improved from baseline (all P < 0.05). Using strict criteria, histological improvement occurred in two-thirds of patients. Pioglitazone was well tolerated; the main side effects were weight gain (averaging 4%) and an increase in total body adiposity. In conclusion, these results indicate that treatment with an insulin-sensitizing agent can lead to improvement in biochemical and histological features of NASH and support the role of insulin resistance in the pathogenesis of this disease. The long-term safety and benefits of pioglitazone require further study.
Cited by 728 works. doi:10.1002/hep.20012 Open-access PDF
Authors
- Kittichai Promrat
- Glen A. Lutchman
- Gabriel Ikponmosa Uwaifo
- Reneé J. Freedman
- Alejandro Soza
- Theo Heller
- Edward C. Doo
- Marc G. Ghany
- Ahalya Premkumar
- Yoon Park
- Jake T. Liang
- Jack Adam Yanovski
- David Erwin Kleiner
- Jay H. Hoofnagle
References
- Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
- Nonalcoholic Steatohepatitis
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
- The Natural History of Nonalcoholic Steatohepatitis: A Follow–Up Study of Forty–Two Patients for Up to 21 Years
- Nonalcoholic steatohepatitis: An expanded clinical entity
- Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans
- Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors